コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ithout spontaneous breathing (prevented by a neuromuscular blocking agent).
2 ing trials, lung-protective ventilation, and neuromuscular blocking agents).
3 nts all had ARDS and had been treated with a neuromuscular blocking agent.
4 ically ventilated children in PICUs received neuromuscular blocking agents.
5 ery of neuromuscular function induced by any neuromuscular blocking agents.
6 d for a safe drug to antagonize all types of neuromuscular blocking agents.
7 he adverse events associated with the use of neuromuscular blocking agents.
8 piratory profiles were anaesthetised without neuromuscular blocking agents.
9 ght complexes in a 1: 1 ratio with steroidal neuromuscular blocking agents.
10 al, many monitors are affected by the use of neuromuscular blocking agents.
11 igned that selectively encapsulate steroidal neuromuscular blocking agents.
12 ects of combining different non-depolarizing neuromuscular blocking agents.
13 eroids in combination with variable doses of neuromuscular blocking agents.
14 ined after discontinuation of treatment with neuromuscular blocking agents.
15 r patients receiving continuous infusions of neuromuscular-blocking agents.
16 unintended extubation in patients receiving neuromuscular-blocking agents.
17 in patients receiving continuous infusion of neuromuscular-blocking agents.
18 specific to patients receiving infusions of neuromuscular-blocking agents.
19 sedation during continuous administration of neuromuscular-blocking agents.
20 of less than 180 mg/dL in patients receiving neuromuscular-blocking agents.
21 in patients with myasthenia gravis receiving neuromuscular-blocking agents.
23 who did not receive a continuous infusion of neuromuscular blocking agent 11%; p < 0.001 by weighted
24 tients who received a continuous infusion of neuromuscular blocking agent 21% vs patients who did not
25 s that a protocol should include guidance on neuromuscular-blocking agent administration in patients
26 Respiratory involvement was more common in neuromuscular blocking agent allergy, while urticaria/an
27 xamined the association between receipt of a neuromuscular blocking agent and in-hospital mortality a
28 tients who received a continuous infusion of neuromuscular blocking agent and patients who did not re
30 e-Dawley rats (age 4 months), treated with a neuromuscular blocking agent and ventilated: control, hy
32 Long-term treatment with nondepolarizing neuromuscular blocking agents and corticosteroids in the
34 o assess the relationship between the use of neuromuscular blocking agents and in-hospital mortality.
36 alysis suggests a modest association between neuromuscular blocking agents and neuromuscular dysfunct
37 ed trial did not show an association between neuromuscular blocking agents and neuromuscular dysfunct
38 ndromes were also associated with the use of neuromuscular blocking agents and prolonged mechanical v
39 f an adverse relationship between the use of neuromuscular blocking agents and skeletal muscle weakne
40 ovenous extracorporeal membrane oxygenation, neuromuscular blocking agents, and positive end-expirato
43 d guidelines and protocols could ensure that neuromuscular blocking agents are used and monitored app
45 an instrumental variable found receipt of a neuromuscular blocking agent associated with a 4.3% (95%
46 studied the ability of four nondepolarizing neuromuscular blocking agents (atracurium, gallamine, me
48 practice suggests that a reduced dose of an neuromuscular-blocking agent be used for patients with m
50 6) Optimal clinical practice suggests that neuromuscular-blocking agents be discontinued prior to t
52 y of muscle function after surgery involving neuromuscular blocking agents can be monitored and, in a
53 ardiac diagnosis among patients who received neuromuscular blocking agents compared with other diagno
54 romuscular weakness and included charges for neuromuscular blocking agents, continuous mechanical ven
55 sistent weight over another when calculating neuromuscular-blocking agent doses in obese patients.
56 ht or adjusted body weight) when calculating neuromuscular-blocking agents doses for obese patients.
58 om retrospective studies suggest that use of neuromuscular blocking agents during general anaesthesia
59 tients who received a continuous infusion of neuromuscular blocking agent experienced longer mechanic
60 n performing BAT in relation to betalactams, neuromuscular blocking agents, fluoroquinolones, chlorhe
62 tion for pain and agitation, 5) sedation and neuromuscular blocking agents for increased work of brea
63 make no recommendation on the routine use of neuromuscular-blocking agents for patients undergoing th
64 s, 'experts' in the clinical pharmacology of neuromuscular blocking agents have advocated routine int
65 predominant one, along with potentiation by neuromuscular blocking agents, immobilization, and proba
66 o describe the use of continuous infusion of neuromuscular blocking agents in mechanically ventilated
70 tanic) contractions in a rat model mimicking neuromuscular blocking agent-induced muscle block used d
72 s (4.6 2.2 d) compared with patients without neuromuscular blocking agent infusions (2.4 2.2 d; p < 0
73 sedation was prolonged in patients receiving neuromuscular blocking agent infusions (4.6 2.2 d) compa
74 resented equivocal evidence on the effect of neuromuscular blocking agent infusions in patients with
75 n completely mediated the negative effect of neuromuscular blocking agent infusions on in-hospital mo
76 per sedation revealed a beneficial effect of neuromuscular blocking agent infusions on mortality (49%
77 eper sedation is a mediator of the effect of neuromuscular blocking agent infusions on mortality.
78 atory distress syndrome patients who receive neuromuscular blocking agent infusions, a prolonged, hig
79 luded, of whom 577 (16.9%) were treated with neuromuscular blocking agent infusions, for a mean (sd)
81 She is placed in the prone position and a neuromuscular blocking agent is administered, without im
82 espiratory infection, early treatment with a neuromuscular blocking agent is associated with lower in
84 therefore aimed to assess whether the use of neuromuscular blocking agents is associated with postope
85 Recent trials suggest that treatment with neuromuscular blocking agents may improve survival in pa
86 nsible for ICU-AW and provides evidence that neuromuscular blocking agents may not be a major cause o
89 suggested that some pairs of nondepolarizing neuromuscular blocking agents might be more efficacious
90 er that irrespective of chemical structural, neuromuscular blocking agents might produce prolonged pa
91 modynamic monitoring and use of sedative and neuromuscular blocking agents, more mechanical ventilati
92 guidelines during use of continuous-infusion neuromuscular blocking agents (NMB) in the intensive car
93 pertoire [10/44 (23%) lacked BSACI compliant neuromuscular blocking agent (NMBA) panels and 17/44 (39
98 e administration of analgesic, sedative, and neuromuscular blocking agents (NMBAs) for each patient.
103 ith a major adverse event whereas the use of neuromuscular blocking agents (NMBAs) was associated wit
104 (EELI) increase after the administration of neuromuscular blocking agents (NMBAs), clinical factors
106 prescriptions of sedative, analgesic, and/or neuromuscular blocking agents; nurse administration of t
107 o significantly more likely to have received neuromuscular blocking agents (p = .004) or propofol (p
108 requirements for vasopressors, sedatives, or neuromuscular blocking agents, percentage of patients th
110 ered one or more sedative, analgesic, and/or neuromuscular blocking agent, range 1-9 drugs, mean 2.5
111 patients receiving a continuous infusion of neuromuscular-blocking agent receive a structured physio
112 neuromuscular blockade: encapsulation of the neuromuscular blocking agent, resulting in inactivation.
113 groups bind tightly to several commonly used neuromuscular blocking agents, such as rocuronium, in aq
115 ted Cox regression analysis found the use of neuromuscular blocking agents to be a significant predic
116 his system have the capability to administer neuromuscular blocking agents to facilitate intubation (
117 est against the routine administration of an neuromuscular-blocking agents to mechanically ventilated
119 ted data included demographics, sedation and neuromuscular blocking agents used, mechanical ventilati
120 e adult cats, anaesthetized, injected with a neuromuscular blocking agent, vagotomized and artificial
121 n the propensity for treatment, receipt of a neuromuscular blocking agent was associated with a reduc
122 with a propensity score approach, the use of neuromuscular blocking agent was found to be a significa
126 tients who received a continuous infusion of neuromuscular blocking agent were more likely to be youn
127 nd route of administration for sedatives and neuromuscular blocking agents were abstracted from ICU f
131 who did not receive a continuous infusion of neuromuscular blocking agent, with a higher frequency of
132 ompare the outcomes of patients treated with neuromuscular blocking agents within the first 2 hospita